Canadian drug developer Cardiome Pharma (CRME) surges 23.5% after announcing it has given...

|About: Cardiome Pharma Corporation (CRME)|By:, SA News Editor

Canadian drug developer Cardiome Pharma (CRME) surges 23.5% after announcing it has given consent for the transfer of North American rights for the development and commercialization of its Vernakalant IV atrial fibrillation drug from Astellas (ALPMY.PK) to Merck (MRK). Cardiome releases earnings after the close today.